CompletedPhase 1ACTRN12607000171415

Activity and Safety of SCH 532706 in HIV-1 Infected Subjects

To evaluate the virologic activity of SCH 532706 coadministered with ritonavir in CCR5-tropic HIV-infected individuals.

Sponsor

Schering-Plough

Enrollment

12 participants

Start Date

Mar 6, 2007

Study Type

Interventional

Conditions

CCR5-tropic HIV-Infected Individuals

Summary

The purpose of this study is to assess the virologic activity, safety, tolerability and pharmacodynmaic profile of SCH 532706 when codminstered with a dose of Ritonavir that could be observed during the treatment of patients with HIV.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests the activity and safety of SCH 532706, an investigational drug for people living with HIV-1. This study is open to both men and women aged 18 to 65. Participation involves taking the study drug and having regular blood tests to monitor your viral load and overall health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This is a single-site, fixed sequence, open label, evaluation of SCH 532706 plus ritonavir. Each patient will receive 20 doses of SCH 532706 and 10 doses of ritonavir over 10 days. SCH 532706 60mg

This is a single-site, fixed sequence, open label, evaluation of SCH 532706 plus ritonavir. Each patient will receive 20 doses of SCH 532706 and 10 doses of ritonavir over 10 days. SCH 532706 60mg administered twice daily as an oral solution (at 2mg/mL) Ritonavir 100mg will be administered once daily as a single capsule. Each patient will be given SCH 532706 morning (AM) and night and Ritonavir each morning (AM) for 10 days.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000171415